Development of a glucagon sensitivity test in humans:Pilot data and the GLUSENTIC study protocol

Autor: Sasha A.S. Kjeldsen, Michael M. Richter, Nicole J. Jensen, Malin S.D. Nilsson, Niklas Heinz, Janus D. Nybing, Frederik H. Linden, Erik Høgh-Schmidt, Mikael P. Boesen, Sten Madsbad, Hendrik Vilstrup, Frank Vinholt Schiødt, Andreas Møller, Kirsten Nørgaard, Signe Schmidt, Elias B. Rashu, Lise L. Gluud, Steen B. Haugaard, Jens J. Holst, Jørgen Rungby, Nicolai J. Wewer Albrechtsen

Publikováno v: Kjeldsen, S A S, Richter, M M, Jensen, N J, Nilsson, M S D, Heinz, N, Nybing, J D, Linden, F H, Høgh-Schmidt, E, Boesen, M P, Madsbad, S, Vilstrup, H, Schiødt, F V, Møller, A, Nørgaard, K, Schmidt, S, Rashu, E B, Gluud, L L, Haugaard, S B, Holst, J J, Rungby, J & Wewer Albrechtsen, N J 2023, ' Development of a glucagon sensitivity test in humans : Pilot data and the GLUSENTIC study protocol ', Peptides, vol. 161, 170938 . https://doi.org/10.1016/j.peptides.2022.170938

A physiological feedback system exists between hepatocytes and the alpha cells, termed the liver-alpha cell axis and refers to the relationship between amino acid-stimulated glucagon secretion and glucagon-stimulated amino acid catabolism. Several re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa7d70f6ae68bbda8b6c4b8ff7a9ceb4
https://pure.au.dk/portal/da/publications/development-of-a-glucagon-sensitivity-test-in-humans(747b7db4-ffca-402a-9e23-693d4956b3dc).html

Studies to develop a glucagon sensitivity test in humans: The GLUSENTIC study protocol

Autor: Sasha A. S. Kjeldsen, Michael M. Richter, Nicole J. Jensen, Malin S. D. Nilsson, Niklas Heinz, Janus D. Nybing, Frederik H. Linden, Erik Høgh-Schmidt, Mikael P. Boesen, Sten Madsbad, Hendrik Vilstrup, Frank Vinholt Schiødt, Andreas Møller, Kirsten Nørgaard, Signe Schmidt, Elias B. Rashu, Lise L. Gluud, Steen B. Haugaard, Jens J. Holst, Jørgen Rungby, Nicolai J. Wewer Albrechtsen

IntroductionA physiological feedback system exists between hepatocytes and the alpha cells termed the liver-alpha cell axis and signifies the role between amino acid-stimulated glucagon secretion and glucagon-stimulated amino acid catabolism. Several

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bdf4f878d57d2fc131a301c3576b5ba3
https://doi.org/10.1101/2022.11.05.22281981

1338-P: Glucoregulatory Disturbances in Autoimmune Liver Disease and Nonalcoholic Fatty Liver Disease Compared with Healthy Individuals

Autor: ANNE-SOFIE H. JENSEN, HENRIETTE YTTING, JOSEPHINE GRANDT, ANDREAS MØLLER, MIKKEL P. WERGE, ELIAS B. RASHU, LIV E. HETLAND, ANDERS JUNKER, LISE HOBOLTH, CHRISTIAN MORTENSEN, FLEMMING TOFTENG, SØREN MØLLER, MOGENS VYBERG, REZA SERIZAWA, LISE GLUUD, NICOLAI J. WEWER ALBRECHTSEN

Publikováno v: Diabetes. 71

Gluco-regulatory disturbances such as hepatic insulin resistance, hyperinsulinemia and prediabetes are commonly present in patients with nonalcoholic fatty liver disease (NAFLD) and those individuals may over time develop full-blown type 2 diabetes.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe26374f987fb03c967e0e4af24acbb7
https://doi.org/10.2337/db22-1338-p

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes

Autor: Nicolai J. Wewer Albrechtsen, Andreas Møller, Christoffer Martinussen, Lise L. Gluud, Elias B. Rashu, Michael M. Richter, Peter Plomgaard, Jens P. Goetze, Sasha Kjeldsen, Lasse Holst Hansen, Finn Gustafsson, Carolyn F. Deacon, Jens J. Holst, Sten Madsbad, Kirstine N. Bojsen‐Møller

Publikováno v: Wewer Albrechtsen, N J, Møller, A, Martinussen, C, Gluud, L L, Rashu, E B, Richter, M M, Plomgaard, P, Goetze, J P, Kjeldsen, S, Hansen, L H, Gustafsson, F, Deacon, C F, Holst, J J, Madsbad, S & Bojsen-Møller, K N 2022, ' Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes ', Diabetes, Obesity and Metabolism, vol. 24, no. 10, pp. 2017-2026 . https://doi.org/10.1111/dom.14789

Sacubitril/valsartan is a neprilysin-inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post-hoc analysis of a 3-year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba6846d3a03bd775f4f6e599570ac24
https://pubmed.ncbi.nlm.nih.gov/35676803

Glucagon Resistance in Individuals With Obesity and Hepatic Steatosis Can Be Measured Using the GLUSENTIC Test and Index.

Autor: Kjeldsen, Sasha A.S., Richter, Michael M., Jensen, Nicole J., Nilsson, Malin S.D., Heinz, Niklas, Nybing, Janus D., Linden, Frederik H., Høgh-Schmidt, Erik, Boesen, Mikael P., Andersen, Thomas L., Johannesen, Helle H., Trammell, Samuel A.J., Grevengoed, Trisha J., Madsbad, Sten, Vilstrup, Hendrik, Schiødt, Frank Vinholt, Møller, Andreas, Rashu, Elias B., Nørgaard, Kirsten, Schmidt, Signe

Publikováno v: Diabetes; Oct2024, Vol. 73 Issue 10, p1716-1727, 12p